$ (452,062,905)

$ (418,727,875)

On January 7, 2019, the Company closed two separate Acquisition Agreements pursuant to which the Company acquired a 51% interest in both Regentys Corporation (“Regentys”) and Olaregen Therapeutix Inc. (“Olaregen”). Regentys is a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders. Olaregen is a New York based regenerative medicine company that is preparing to launch its proprietary, patented, wound conforming gel matrix, Excellagen, an FDA 510K cleared wound healing product.

Majority interest

77.00%

Majority interest

51.00%

Organization of Business and Going Concern (Details Narrative) - USD ($)	Jan. 07, 2019	Jul. 31, 2020	Oct. 31, 2019	Jul. 31, 2019	Jan. 18, 2017
Accumulated deficit		$ (452,062,905)		$ (418,727,875)
Working capital deficiency		$ (40,100,000)
Secured promissory note Description	On January 7, 2019, the Company closed two separate Acquisition Agreements pursuant to which the Company acquired a 51% interest in both Regentys Corporation (“Regentys”) and Olaregen Therapeutix Inc. (“Olaregen”). Regentys is a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders. Olaregen is a New York based regenerative medicine company that is preparing to launch its proprietary, patented, wound conforming gel matrix, Excellagen, an FDA 510K cleared wound healing product.
Olaregen
Majority interest			77.00%
Hema Diagnostic Systems, LLC
Majority interest					51.00%